 
 Title: Safety, Tolerability and Effects  of a Single Subcutaneous Administration of SP16–a 
SERPIN -like, Small Peptide Agonist of the Low Density Lipoprotein- like Receptor 1  –on the 
Acute Inflammatory Response in Patients with ST- segment Elevation Myocardial Infarction 
(STEMI)  
 
NCT  #: 04225533  
 
Document  date: August 21,2020  
 
Document Type: Pr otocol 
 
 
 
Safety, Tolerability, and Efficacy of SP16  in STEMI  
Protocol Number [ADDRESS_1251819] 21, 2020   
 Confidential  
  
Safety, Tolerability and Effects  of a Single 
Subcutaneous Administration of SP16 –a SERPIN -
like, Small Peptide Agonist of the Low Density 
Lipoprotein -like Receptor 1  –on the Acute 
Inflammatory Response in Patients with ST -segment 
Elevation Myocardial Infarction (STEMI)  
 
Protoc ol Identifying Number: 0 2-SP16 
 
SP16 Inflammatory Response Inhibition Trial 
(SPI[INVESTIGATOR_61192])  
 
 Principal Investigator s: 
Antonio Abbate, MD, PhD  
Benjamin W. Van Tassell, PharmD  
 
 IND/IDE Sponsor: Serpin Pharma, LLC  
 
Version Number:  v.[ADDRESS_1251820] OF ABBREVIATIONS  ............................................................................................................................. 4  
STATEMENT OF COMPLIANCE  ..................................................................................................................... 7  
PROTOCOL SUMMARY  .................................................................................................................................. 8  
1 KEY ROLES  ........................................................................................................................................... 10 
2 INTRODUCTION: BACKGROUND INFORMATION AND SCIENTIFIC RATIONALE  ........................ 11 
2.1 BACKGROUND  INFORMATION  ................................................................................................... 11 
2.2 RATIONALE  .................................................................................................................................. 13 
2.3 POTENTIAL  RISKS  AND  BENEFITS  ............................................................................................ 14 
2.3.1 KNOWN POTENTIAL RISKS  .................................................................................................... 14 
2.3.2 KNOWN POTENTIAL BENEFITS  ............................................................................................. 14 
3 OBJECTIVES AND PURPOSE  ............................................................................................................. 15 
4 STUDY DESIGN AND ENDPOINTS  ..................................................................................................... 15 
4.1 DESCRIPTION  OF THE  STUDY  DESIGN  .................................................................................... 15 
4.2 STUDY  ENDPOINTS  ..................................................................................................................... 15 
4.2.1  PRIMARY ENDPOINT  .............................................................................................................. 15 
4.2.2 SECONDARY ENDPOINTS  ..................................................................................................... 15 
4.2.3 PHARMACOKINETIC ASSESSMENT ...................................................................................... 16 
5 STUDY ENROLLMENT AND WITHDRAWAL  ...................................................................................... 16 
5.1 PARTICIPANT  INCLUSION  CRITERIA  ......................................................................................... 16 
5.2 PARTICIPANT  EXCLUSION  CRITERIA  ....................................................................................... 16 
5.3 STRATEGIES  FOR  RECRUITMENT  AND  RETENTION  .............................................................. 17 
5.3.1 SCREENING  ............................................................................................................................. 17 
5.3.2  CONSENTING  .......................................................................................................................... 17 
5.3.3 STUDY DRUG ADMINISTRATION  ........................................................................................... 17 
5.4 PARTICIPANT  WITHDRAWAL  OR TERMINATION  ..................................................................... 17 
5.4.1 REASONS FOR WITHDRAWAL OR TERMINATION  .............................................................. 18 
5.4.2 HANDLING OF PARTICIPANT WITHDRAWALS OR TERMINATION  .................................... 18 
5.5 PREMATURE  TERMINATION  OR SUSPENSION  OF STUDY  ..................................................... 18 
6 STUDY AGENT  ...................................................................................................................................... 18 
6.1 STUDY  AGENT(S)  AND  CONTROL  DESCRIPTION  .................................................................... [ADDRESS_1251821] STORAGE AND STABILITY  .................................................................................. 19 
6.1.4 PREPARATION  ......................................................................................................................... 19 
6.1.5 DOSING AND ADMINISTRATION  ............................................................................................ 19 
6.1.6 ROUTE OF ADMINISTRATION ................................................................................................ 19 
6.1.7 DOSE  ........................................................................................................................................ 19 
6.1.8 DURATION OF THERAPY  ....................................................................................................... 20 
6.1.9 TRACKING OF DOSE  .............................................................................................................. 20 
6.2 STUDY  AGENT  ACCOUNTABILITY  PROCEDURES  ................................................................... 20 
7 STUDY PROCEDURES AND SCHEDULE  ........................................................................................... 20 
7.1 STUDY  PROCEDURES/EVALUATIONS  ...................................................................................... [ADDRESS_1251822] OF CARE STUDY  PROCEDURES  ................................................................. 20 
7.2 LABORATORY  PROCEDURES/EVALUATIONS  ....................................................................... [ADDRESS_1251823] 21, 2020   
Confidential  3 7.2.2 OTHER ASSAYS OR  PROCEDURES  ................................................................................... 21 
7.2.3 SPECIMEN PREPARATION, HANDLING, AND STORAGE  ................................................... 21 
7.2.4 SPECIMEN SHIPMENT  ............................................................................................................ 21 
7.3 STUDY  SCHEDULE  ...................................................................................................................... 22 
7.3.1 SCREENING  ............................................................................................................................. 22 
7.3.2 DOSING (after PCI) ................................................................................................................... 22 
7.3.3 DISCHARGE (or [ADDRESS_1251824])  .................................................................. 22 
7.3.4 VISIT 4: FOLLOW -UP VISIT (Day 14+/ - 2) ............................................................................... 22 
7.3.4 VISIT 5: FOLLOW -UP VISIT 2 (Day 90+/ -14) ........................................................................... 23 
7.3.5 VISIT 6: FOLLOW -UP VISIT 3 (Day 365 +/ - 30)....................................................................... 23 
7.3.6 SCHEDULE OF EVENTS TABLE  ............................................................................................. 23 
7.4 CONCOMITANT  MEDICATIONS,  TREATMENTS,  AND  PROCEDURES  .................................... 24 
7.5 JUSTIFICATION  FOR  USE  OF PLACEBO  ................................................................................... 24 
7.5.1 PRECAUTIONARY MEDICATIONS, TREATMENTS, AND PROCEDURES  .......................... 24 
7.6 PROHIBITED  MEDICATIONS,  TREATMENTS,  AND  PROCEDURES ......................................... 24 
7.7 PROPHYLACTIC  MEDICATIONS,  TREATMENTS,  AND  PROCEDURES  .................................. 24 
7.8 RESCUE  MEDICATIONS,  TREATMENTS,  AND  PROCEDURES  ................................................ 24 
7.9 PARTICIPANT  ACCESS  TO STUDY  AGENT  AT STUDY  CLOSURE  .......................................... 24 
8 ASSESSMENTS OF SAFETY  ............................................................................................................... 24 
8.1 SPECIFICATION  OF SAFETY  PARAMETERS  ............................................................................. 24 
8.1.1 DEFINITION OF ADVERSE EVENTS (AE)  .............................................................................. 24 
8.1.2 DEFINITION OF SERIOUS ADVERSE EVENTS (SAE)  .......................................................... 25 
8.1.3 DEFINITION OF UNANTICIPATED PROBLEMS (UP)  ............................................................ [ADDRESS_1251825]  ........................................................................................... 28 
8.4.5 REPORTING OF PREGNANCY  ............................................................................................... 28 
8.5 STUDY  HALTING  RULES  ............................................................................................................. 28 
8.6 SAFETY  OVERSIGHT  ................................................................................................................... 29 
8.7   ADJUDICATION  OF CLINICAL  EVENTS ..................................................................................... 29 
8.7.1 Event -adjudicating committee  ................................................................................................... 29 
8.7.2 Definition of the events  .............................................................................................................. 29 
8.7.3 Implications of the findings of the event -adjudicating committee  .............................................. 30 
9 CLINICAL MONITORING  ...................................................................................................................... 30 
10  STATISTICAL CONSIDERATIONS  .................................................................................................. 30 
10.1 ANALYSIS  DATASETS  ................................................................................................................. 30 
10.2 DESCRIPTION  OF STATISTICAL  METHODS  .............................................................................. 30 
10.2.1  GENERAL APPROACH ........................................................................................................ 30 
11 SOURCE DOCUMENTS AND ACCESS TO SOURCE DATA/DOCUMENTS  ..................................... 31 
12 QUALITY ASSURANCE AND QUALITY CONTROL  ........................................................................... 31 
13 ETHICS/PROTECTION OF HUMAN SUBJECTS  ................................................................................. [ADDRESS_1251826] 21, 2020   
Confidential  4 13.3.1  CONSENT/ASSENT AND OTHER INFORMATIONAL DOCUMENTS PROVIDED TO 
PARTICIPANTS  .................................................................................................................... [ADDRESS_1251827] 21, 2020   
 Confidential  4  
SUMMARY OF CHANGES  
 Changes to prior version 27 March 2020  Changes necessary to address COVID19 Pandemic Risk. Enrollment to resume when IRB approval obtained. 
 
 
Section  Change  Rationale  
Section 5.2  Updated exclusion criteria to include 
COVID -19. Specify criteria for COVID -19 
exclusion.  
Section 7.3.6  New section  Need to explain need to comply with 
SARS -CoV2 screening and testing 
practice at VCU Health  
Section 7.3.7  Table of events updated  Updated with changes  
Figure 1  Updated PK times to 0, 30, 60 & 180 
minutes  Updated with changes  
Section 4.2.3  Updated PK times to 0, 30, 60 & 180 
minutes  Updated with changes  
Section 7.3.2  Updated PK times to 0, 30, 60 & 180 
minutes  Updated with changes  
Schedule of 
Events Table  Updated PK times to 0, 30, 60 & 180 
minutes  Updated with changes  
  Changes to prior version 13 December 2019  Changes in response to COVID19 Pandemic Emergency – All changes planned to revert when emergency resolved.  
 Enrollment has been halted on 3/23/2020.  
Sectio n Change  Rationale  
Section s 4.2.2, 7.3.5, 7.3.[ADDRESS_1251828]  Aspartate aminotransferase  
AUC∞ Total area-under -the-curve  
CFR  
CRF  Code of Federal Regulations  
Case Report Forms  
CK-MB Creatine Kinase -Myocardial Band  
CL tot Total clearance  
cmax 
CRP  Maximum concentration  
C-Reactive Protein  
DSMB  Data Safety Monitoring Board  
ECG  Electrocardiogram  
FDA  Food and Drug Administration  
GCP  Good Clinical Practice  
GMP  
ICH 
IDS 
IND    Good Manufacturing Practice  
   International Council of Harmonis ation  
Investigational Drug Services 
Investigational New Drug  
IRB Institutional Review Board  
LAD  
LRP1  
MOP  Left Anterior Descending artery  
Low Density Lipoprotein Receptor- like Protein [ADDRESS_1251829]-segment E levation  Myocardial Infarction  
t1/[ADDRESS_1251830] 21, 2020   
 Confidential  7 STATEMENT OF COMPLIANCE  
 
The trial will be carried out in accordance with Good Clinical Practice (GCP) as required by 
[CONTACT_209060] (US) Code of Federal Regulations (CFR) applicable to clinical studies (45 CFR Part 46, 21 CFR Part 50, 21 CFR Part 56, 21 CFR Part 312, and/or 21 CFR Part 812) and International Conference on Harmonisation Guidance for Industry, Good Clinical Practice: Consolidated Guidance.  
 
All key personnel (all individuals responsible for the design and conduct of this trial) have completed Human Subjects Protection Training. 
 I agree to ensure that all staff members involved in the conduct of this study are informed about their obligations in meeting the above commitments. 
  
Principal  
Investigator:  [INVESTIGATOR_516826], MD, PhD 
   Print/Type Name  
 
 [CONTACT_125216]: [INVESTIGATOR_893712], PharmD  
 Print/Type Name 
  
[INVESTIGATOR_14586]:       D
 ate/Signature 
  
    D
 ate/Signature 
[CONTACT_242722], Tolerability, and Efficacy of SP16  in STEMI  
Protocol Number [ADDRESS_1251831] 21, 2020   
 Confidential  8 PROTOCOL SUMMARY 
 
 
Title: Safety, Tolerability and Effects of a Single Subcutaneous Administration of 
SP16 –a SERPIN -like, Small Peptide Agonist of the Low Density Lipoprotein-
like Receptor 1 –on the Acute Inflammatory Response in Patients with ST-
segment Elevation Myocardial Infarct ion (STEMI) 
 
Design:  Single -center, single -arm, open -label, clinical trial of SP16 0.2 mg/Kg 
administered within 6 hours of reperfusion .  
 
Objectives:                       The primary objective is to determine the effects of SP16 on the area -under -
the-curve (AUC) for C -reactive protein (CRP) at 14 days as compared with 
historical controls treated with placebo in the VCUART, VCUART2, and VCUART3 studies. Secondary objectives include the assessment of the effects of SP16 on AUC for creatine kinase myocardial band (CK-MB) at 72 hours.  
 
Study 
Endpoints:  • AUC for CRP at 14 days  [primary endpoint]  
• AUC for CK -MB at 72 hours 
• Pharmacokinetics  
• Safety assessments  
• Echocardiography at 365 days 
• Incidence of heart failure at 365 days 
 
Safety 
Monitoring: Subjects will be monitored directly for at least 12-hours after administration of 
investigational medication and then have repeated follow-up at 72 hours, 14 days, and 365 days.  
 
Population:   Adult (>21 years of age) i ndividuals (N= 10) with acute ST -segment elevation 
myocardial infarction (within 12 hours of symptom onset).  
 
Phase:  1B/2A 
 
Number of Sites 
Enrolling Participants  1 (Virginia Commonwealth University)  
  
 
Description  of 
Study Agent: SP16 is a synthetic oligopeptide based upon the structure of human alpha -1 
antitrypsin. SP16 exhibits high affinity for the LRP1. 
 
Study  Duration:  Primary Endpoint: 14 days 
Safety Endpoint: 14 days Long- term Follow -up: [ADDRESS_1251832] patient enrolled 
 
Participant  
Duration:  [ADDRESS_1251833] 21, 2020   
 Confidential  9  
    Figure 1: Schematic of the Study Design  
 
  
 
 
       

Safety, Tolerability, and Efficacy of SP16  in STEMI  
Protocol Number [ADDRESS_1251834] 21, 2020   
 Confidential  10  
1 KEY ROLES  
 Principal Investigators:  Antonio Abbate, MD, PhD  
James C. Roberts, Esq., Professor in Cardiology  
Department of Internal Medicine  
Virginia Commonwealth University  
[ADDRESS_1251835]  
Richmond, VA [ZIP_CODE]  Benjamin Van Tassell, PharmD  
Professor and Vice Chair for Clinical Research  
Department of Pharmacotherapy & Outcomes Science  
Virginia Commonwealth University  
[ADDRESS_1251836] 21, 2020   
 Confidential  11  
2 INTRODUCTION: BACKGROUND INFORMATION AND SCIENTIFIC RATIONALE  
 
2.[ADDRESS_1251837] -segment elevation ( STEMI) are at particularly high risk for adverse 
cardiac remodeling, heart failure, and mortality.
1,[ADDRESS_1251838] been considerable 
improvements in the treatment of STEMI, the reduction in early mortality has been associated with an increasing inci dence of heart failure after STEMI.
1 This likely reflects more high -risk patients 
surviving the index event as well as the aging of the population and the epi[INVESTIGATOR_893713]. Within 1 year of STEMI, more than 20% of survivors are diagnosed with heart failure, a disease associated with high morbidity, disability, and mortality.
[ADDRESS_1251839] to other cardiovasc ular disease, the incidence and prevalence of heart 
failure continue to increase and heart failure is now the leading cause of hospi[INVESTIGATOR_893714] ≥ [ADDRESS_1251840] productivity and increasing costs of medical care, heart failure imposes a significant burden on healthcare.  There is an urgent need to develop additional treatments to prevent heart failure after AMI.
2 The 
current treatment in STEMI includes prompt reperfusion of the ischemic myocardium by [CONTACT_893726] (i.e. angioplasty or fibrinolysis), prevention of re-occlusion (i.e. antiplatelet and anticoagulants), and neurohormonal blockade (i.e. renin-angiotensin-aldosterone and adrenergic blockers). While each of these interventions provide incremental benefit and significantly reduce morbidity and mortality, the incidence of heart failure after STEMI has continued to rise, impl ying that the current treatment paradigm still misses one or 
more key pathophysiologic mechanisms. Determining the mechanisms by [CONTACT_893727][INVESTIGATOR_893715] a critical step in the search  for novel interventions, with the ultimate goal of reducing the incidence, burden, and 
mortality of heart failure after STEMI.
[ADDRESS_1251841] 
failed, we propose a novel and substantially different approach to modulat ing the inflammatory 
response based upon the anti-inflammatory and cytoprotective properties of alpha-1 antitrypsin (AAT).
5  
 AAT is a naturally occurring anti- inflammatory protein that is abundant in the plasma and  exerts 
powerful cytoprotective effects in endothelial cells, cardiomyocytes and fibroblasts.
5 In an 
experimental model of acute myocardial infarction (AMI), AAT administered at the onset of ischemia or at time of reperfusion led to a significantly smaller  infarct size and more favorable 
cardiac healing and remodeling.
6  
 The mechanism by [CONTACT_893728] 1 (LRP1) receptor. Serpin Peptide 16 (SP16) is  a synthetic anti -inflammatory peptide developed to reproduce the - anti-inflammatory and 
α activities of the Serine Protease Inhibitors (SERPI[INVESTIGATOR_893716]), such as AAT. Serpi[INVESTIGATOR_893717] a 
family of proteins characterized by [CONTACT_893729], thrombin, plasmin.
7 When Serpi[INVESTIGATOR_893718], causing a conformational change by [CONTACT_9444] a short peptide containing a unique motif (5-11 amino -acids) is exposed.
8,9 This motif binds to LRP1, a membrane receptor responsible for 
clearance of plasma proteins and for inducing an anti- inflammatory and  cytoprotective signal.9  
Serpin Pharma has developed a synthetic anti-inflammatory peptide (SP16) that contains the properties of the Serpin core motif responsible for the anti- inflammatory and cyto -protective 
signaling, without inhibiting the plasma serine proteases (Issued Patent #8,975,224). SP16 is [ADDRESS_1251842] oligopeptide maintaining activity and a single amino acid substitution enhancing anti- inflammatory signaling 
and plasma stability. In vitro, SP16 did not exhibit meaningful affinity for receptors other than LRP-1.  
 From a safety perspective, SP16 appears to bind exclusively to LRP-1. A survey of >[ADDRESS_1251843] not been detected in animal models after up to 6 months of treatment. Furthermore, deliberate attempts to produce anti-SP16 monoclonal antibodies failed to provoke an immune response.  In comparison with AAT , SP16 is a bio-superior- small peptide which retains the anti-
inflammatory and cytoprotective properties of Serpi[INVESTIGATOR_2115]. SP16 only contains the LRP-1 binding motif, thus providing specific anti- inflammatory actions without serine protease inhibition.
 
SP16 has demonstrated anti-inflammatory properties in several pre-clinical models. In ex vivo peripheral blood mononuclear cells derived from a collagen antibody induced arthritis mouse model, SP16 significantly reduced LPS- stimulated tumor necrosis factor (TNF) -α and Interleukin 
(IL)-6 production compared to vehicle and no treatment. SP16 has also been tested in db-/db 
diabetic mice, in which it significantly reduces serum amyloid A, an acute phase reactant, and monocyte chemotactic protein-1. Moreover, SP16 reduced IL-[ADDRESS_1251844] sizes and better left ventricular systolic function at 24 hours and 7 days.  SP16 has been studied extensively in non-clinical toxicology studies. A single subcutaneous 
administration of SP16 at doses up to 60 mg/kg in Sprague- Dawley rats with a [ADDRESS_1251845] article - related  findings were limited to increased incidence of 
slight edema i njection site in males given 60 mg/kg, minimal decreases in albumin in males given 
60 mg/kg, minim al increases in total cholesterol and triglycerides in females given ≥ 20 mg/kg, and 
microscopic changes at the injection site - a mild but increased severity of inflammation  occurred in 
animals given 60 mg/kg, eosinophilic material and mild necrosis in subcutis of animals given ≥5 mg/kg). The mild necrosis in the subcutis noted in males administered 60 mg/kg and in females administered ≥5 mg/kg was considered adverse.  
 2.2 RATIONALE  
 The main hypothesis of this study is that a single subcutaneous administration of SP16 0.2 mg/kg is safe and well  tolerated in patients with STEMI and associated with a reduction in the acute 
inflammatory response to STEMI, as measured  as area -under-the- curve (AUC) for C reactive 
protein (CRP), the preferred inflammatory marker for cardiovascular risk prognostication. SP16 will be administered subcutaneously as this route has greater ease of administration than intravenous injection . A single dose administration has been selected based upon pre- clinical data 
and expected clinical use of SP16.   The dose of SP16 was chosen  based on the results of a Phase I trial  (NCT [STUDY_ID_REMOVED], WIRB® 
Protocol #20181644) in which 3 cohorts of healthy volunteers received a single subcutaneous injection of SP16 or placebo: SP16 0.0125 mg/kg (n=6), 0.050 mg/kg (n=6), 0.200 mg/kg (n=6), or placebo (n=6). Safety assessments were performed throughout 12 hours of continuous monitoring followed by [CONTACT_893730] 24 hours, 3 days, and 7 days. None of the SP16 doses showed any significant effects on any of the safety parameters as measured by [CONTACT_893731], complete blood count, liver function tests, thromboelastography, coagulation testing, electrocardiogram, and cardiac biomarkers (high sensitivity troponin I, CK- MB). All doses were 
well-tolerated and no patient reported injection site pain greater than 1/[ADDRESS_1251846] -segment elevation myocardial infarction  treated with 
plasma derived AAT
11 the treatment was administered at a dose of 60 mg/kg, which is equimolar to 
an SP16 dose of 2 mg/kg. The 60 mg/kg dose of plasma-derived AAT  was well -tolerated .11 Thus, 
the SP16 dose of 0.2 mg/kg is l ess than the equivalent dose of plasma- derived AAT  which was 
well tolerated  in the 10 patient Phase 1 clinical trial.  However, in experimental settings SP16 was 
>20-fold more powerful than plasma derived AAT at an equimolar dose and >500-fold more 
powerful per mg of drug.[ADDRESS_1251847] 21, 2020   
 Confidential  14 2.3 POTENTIAL RISKS AND BENEFITS  
 
2.3.1 KNOWN POTENTIAL RISKS  
 
Allergic reaction to any drug, including SP16, is possible, and severe allergic reactions can be life 
threatening.  
 The dose of SP16 was chosen  based on the results of a Phase I trial in which 3 cohorts of healthy 
volunteers received a single subcutaneous injection of SP16 or placebo: SP16 0.0125 mg/kg (n=6), 0.050 mg/kg (n=6), 0.200 mg/kg (n=6), or placebo (n=6). Safety assessments were performed throughout 12 hours of continuous monitoring followed by [CONTACT_893730] 24 hours, 3 days, and 7 days. None of the SP16 doses showed any significant effects on any of the safety parameters as measured by [CONTACT_893731], complete blood count, liver function tests, thromboelastography, coagulation testing, electrocardiogram, and cardiac biomarkers (high sensitivity troponin I, CK- MB). All doses were well -tolerated and no patient reported injection 
site pain greater than 1/[ADDRESS_1251848] common adverse reactions to plasma derived AAT  (to which SP16 is 
related) occurring in >1% subjects were headache (7%), musculoskeletal discomfort (myalgias)  
(7%) and sore throat (pharyngitis) (2%). Rash, hot flushing and pruritus (itching) may also occur (<1%). All these reactions were considered mild or moderate and not s evere and  were self -
limiting with the end of the infusion .
12 An elevation in the aminotransferase levels (ALT or AST) 
may occur (10%) deriving from subtle alterations in the muscles and/or liver. Such elevations were minor (less than 5 -times baseline), tra nsient (resolve within 3 months) and did not result in 
symptoms or any long-term consequences. Similar to any drug or intervention, the possibility of an unanticipated adverse reaction cannot be excluded.  There is a possibility that an assessment complete d during the screening phase will reveal an 
unrecognized disease or condition (i.e. pregnancy). The results of the tests will be discussed with the subject, and if requested, forwarded  to a chosen physician. 
 Loss of confidentiality is a potential risk. The likelihood of this occurring, however, is very low. Except when required for clinical practice or by [CONTACT_2371], subjects will not be identified by [CONTACT_2300], 
social security number, address, telephone number or any other personal identifier. Study related tests may be reported but subjects will not be identified.   There is minimal risk associated with the physical procedures of the study. Additional blood draws may be needed as part of the study. The blood draws may result in minor bleeding or discomfort (rare) and infection (extremely rare) at puncture site. When p ossible, blood will be 
drawn from an existing  indwelling peripheral venous catheter.  
 2.3.[ADDRESS_1251849] 21, 2020   
 Confidential  15 3 OBJECTIVES AND PURPOSE  
 
The primary objective of this study is to assess the effects  of a single subcutaneous dose of SP16 on 
the acute inflammatory response in patients with STEMI . 
 4 STUDY DESIGN AND ENDPOINTS  
 
4.1 DESCRIPTION OF THE STUDY DESIGN  
 
We designed a single-center, single- arm, open -label study of a single subcutaneous administration 
of SP16 (0 .2 mg/kg) in patients with STEMI. Patients will be eligible within if undergoing PCI 
within [ADDRESS_1251850] pain onset and if able enrolled and treated within 6 hours of PCI. 
Biomarkers will be obtained at admission, and up to 72 hours (or at discharge whichever comes 
first), and at 14± [ADDRESS_1251851] chemiluminescent technology at admission, immediately after PCI, and every 6 hours until 72 hours (when available). CK- MB peak value will be defined as the maximal 
CK-MB level measured dur ing hospi[INVESTIGATOR_059]. For patients with fewer than [ADDRESS_1251852] the 
typi[INVESTIGATOR_893719] -MB curve.14 The time -to-CK-MB peak, as a measure of duration of 
myocardial injury, will be considered as the time between the initial onset of symptoms (chest pain per patient report) and the CK- MB peak level.  
Safety, Tolerability, and Efficacy of SP16  in STEMI  
Protocol Number [ADDRESS_1251853] 21, 2020   
 Confidential  16  
A transthoracic echocardiogram will be performed at baseline and 365 days. The echocardiogram will measure left and right ventricular and atrial dimensions, left and right ventricular systolic function, transmitral flow Doppler spectra, mitral and tricuspi[INVESTIGATOR_199539], ejection time and stroke volume, inferior vena cava, aorta and pulmonary artery diameters and Doppler spectra, according to the recommendations of the American Society of Echocardiography
.15 Results from clinically indicated studies will be  used for baseline 
measurements.  
 4.2.3 PHARMACOKINETIC ASSESSMENT  
 A dedicated tube of blood will be collected to measure SP16 concentration at baseline, 30, 90 minutes, and 180 minutes. Pharmacokinetic data will be analyzed using non- compartmental 
analysis. This approach will yield estimates of pharmacokinetic parameters such as total clearance (CLtot), cmax (maximum concentration), tmax (time to Cmax), mean resident time (MRTsys), volume of distribution of the central compartment (Vdcc), volume of distribution at pseudo- steady -state (Vdpss), volume of distribution at steady- state (Vdss), total area -under-the-
curve (AUC ∞), half -life (t1/2), and terminal rate constant ( λ) without having to specify a 
particular compartment model.  
 
[ADDRESS_1251854] meet ALL  
 the 3 criteria :  
 
1) Presentation to the hospi[INVESTIGATOR_199538] (or equivalent) with an onset within [ADDRESS_1251855] segment elevation (>1 mm) in 2 or more anatomically contiguous leads that is new or presumably new (for intermittent pain lasting more than 12 hours, the time from the when the pain became severe and constant);  
2) Coronary intervention planned and/or completed within 12 hours of symptom onset, and enrollment in the study within 6 hours of angiogram (max 18 hours from symptom onset) 
3) Age>21years (NIH standard) 
 
5.[ADDRESS_1251856] meet NONE  
 of the Exclusion criteria.  
 
- Inability to give informed consent 
- Hemodynamic instability as defined as need for inotropic or vasoactive agents, or need for mechanical support devices (including intra- aortic balloon pump) 
- Pregnancy or breastfeeding  
- Preexisting congestive heart failure (AHA/ACC class C -D, [LOCATION_001] Heart Association III -
IV) 
- Preexisting severe left ventricular dysfunction (EF<20%) 
- Preexisting severe valvular heart disease  
- Known active infections (acute o r chronic) including known COVID-[ADDRESS_1251857] 21, 2020   
 Confidential  17 in the prior 3 weeks (PCR testing results from current admission can be used but are not 
required) 
- Recent (<14 days) or active use of immunosuppressive drugs (including but not limited to 
high-dose corticosteroids [>1 mg/kg of prednisone equivalent], TNF- α  blockers, 
cyclosporine) not including NSAIDs or corticosteroids used for IV dye allergy only) 
- Recent (<14 days) or active use of anti -inflammatory drugs (not including NSAIDs or 
corticosteroids used for IV dye allergy only) 
- Known chronic inflammatory disease (including but not limited to rheumatoid arthritis, 
systemic lupus erythematosus) 
- Known active malignancy of any type, or prior diagnosis in the past 10 years 
- Neutropenia (absolute neutrophil count<1,800/mm3 [or <1,000/mm3 in African American patients])  
- Severe impairment in renal function (estimated glomerular filtration rate <30 ml/kg*min)  
- Anticipated need fo r cardiac or major surgery  
- Known Allergy to SP16 
 
5.3 STRATEGIES FOR RECRUITMENT AND RETENTION  
 
5.3.1 SCREENING  
 
All patients with suspected STEMI at VCU Health are identified with an alert system sent out to the on- call staff and the research team, call “Alpha Alert ”. We will obtain a partial waiver for 
screening to prospectively identify subjects that may meet the inclusion criteria and access the electronic health records , if required by [CONTACT_4707]. Every possible effort will 
be made to protect the privacy and confidentiality of the subjects. The information of those subjects who screen out or who decide to not enroll will be immediately discarded. Those who are found to be eligible and express interest in the study will be approached for consent.  
 
5.3.[ADDRESS_1251858] consenting. Those individuals unable to provide consent and in whom a legally authorized representative cannot be found to consent will be excluded from the study. Potential participants will be approached as soon as possible after screening (including before catheterization) to discuss participation and obtain informed consent. However, patients will not receive treatment with SP16 upon successful completion of catheterization and completion of all screening criteria. Only appropriately trained investigators will attempt to obtain informed consent to participate in the study. 
 
5.3.3 STUDY DRUG ADMINISTRATION  
 Following screening and enrollment, the local investigational pharmacy will prepare the study drug for administration (0.2 mg/kg, up to 12 mg maximum). The drug will be administered by [CONTACT_893732][INVESTIGATOR_533372].  
 
5.[ADDRESS_1251859] 21, 2020   
 Confidential  18  
Participants may withdraw voluntarily from the study or the PI [INVESTIGATOR_92930] a participant from the study. 
 5.4.1 REASONS FOR WITHDRAWAL OR TERMINATION  
 Participants are free to withdraw from participation in the study at any time . An 
investigator may terminate participation in the study if: 
• Any clinical adverse event (AE), laboratory abnormality, or other medical condition or situation occurs such that continued participation in the study would not be in the best interest of the participant 
• The participant meets an exclusion criterion (either newly developed or not previously recognized) that precludes further study participation.  
 
Halting criteria for study conduct are described separately in Section s Error! 
Reference source not found.  and Error! Reference source not found. . 
 5.4.[ADDRESS_1251860] ( IRB) and will provide the reason(s) for the termination or 
suspension.  Circumstances that m ay warrant termination or suspension include, but are not limited to 
determination of unexpected, significant, or unacceptable risk to participants.  Study may resume once concerns about safety, protocol compliance, and data quality are addressed and satis fy the sponsor, IRB and/or FDA. Specific halting rules are described in 
Section Error! Reference source not found. . 
 
6 STUDY AGENT  
 
6.1 STUDY AGENT(S) AND CONTROL DESCRIPTION  
 
6.1.[ADDRESS_1251861] 21, 2020   
 Confidential  19 SP16 will be supplied by [CONTACT_893733] 
(IDS) Pharmacy of Virginia Commonwealth University.  
 
6.1.2 FORMULATION, APPEARANCE, PACKAGING, AND LABELING  
 Investigational SP16 will be prepared by [CONTACT_893734]. The pharmacy at the clinical site (VCU) will transfer the drug (SP16) from the vial into a tube in preparation for the injection.   
 
6.1.[ADDRESS_1251862] STORAGE AND STABILITY  
 The drug is stored in 4.5 mL, brown vials in -20
oC.  The drug is formulated in water, pH 5.8-6.2, 
at 3 mg/mL. Final volume in each vial is 2.[ADDRESS_1251863] 25, 2017.  The API [INVESTIGATOR_893720] 12  and 24 months since manufacturing 
was found to be essentially unchanged. The expi[INVESTIGATOR_893721] 12/31/2021.  
 
  6.1.4 PREPARATION  
 SP16 API w ill be  re-suspended in double distilled water  and pH wa s adjusted to pH 5.9 ± 0.02 by 
[CONTACT_1583] 0.1M hydrochloric acid and/or 0.1M sodium hydroxide solution slowly. For complete details of formulation and sterile -fill-finish, please see MTA 172-[ADDRESS_1251864] will receive a single, weight -based dose of SP16  administered  by [CONTACT_205291]  (0.2 mg/kg, up to a maximum of 12 mg).  
 6.1.6 ROUTE OF ADMINISTRATION  
 SP16 will be administered by [CONTACT_22666] .  
 6.1.7 DOSE  
 SP16 will be administered at a dose of 0.2 mg/kg (up to a maximum of 12 mg).
 SP16 is 
formulated as a 2 -mL syringe containing 6 mg of SP16 (3 mg/mL) , such that all  patients will 
require [ADDRESS_1251865] 21, 2020   
 Confidential  20  
6.1.8 DURATION OF THERAPY 
 All subjects will receive a single dose of SP16 (consist ing of 2 injections given in the same 
session) . Additional dos es will not be administered.  
 6.1.[ADDRESS_1251866] at VCUHealth. Tracking of all incoming doses, dispensed doses, administered dose and wasted doses will be handled by [CONTACT_893735]. A single shipment of all investigational doses will be delivered by [CONTACT_893736]. Any unused syringes will be returned to Serpin Pharma LLC at the end of the study period. 
 7 STUDY PROCEDURES AND SCHEDULE   
 
7.1 STUDY PROCEDURES/EVALUATIONS  
 7.1.1 STUDY SPECIFIC PROCEDURES  
 The following research procedures will be performed. 
 
• Medical history  through patient interview, and if available, medical record review by a 
licensed study physician. 
• Medication history as reported by [CONTACT_102], and if available, through pharmacy refill records  by a licensed study physician. 
• A complete review of systems and physical examination  will be performed by a 
licensed study physician. 
• A 12- lead electrocardiogram (ECG) will be reviewed by [CONTACT_473]. 
• Blood sample collection for comprehensive metabolic panel, complete blood cell count, coagulation tests, cardiac injury markers and pharmacokinetics  will be performed by a 
registered nurse. Blood samples will be drawn from an indwelling venous catheter when possible.
 
 
7.1.[ADDRESS_1251867] of care for STEMI , and these procedures will be charged to the 
patient or insurance, as applicable.   This may include: 
Safety, Tolerability, and Efficacy of SP16  in STEMI  
Protocol Number [ADDRESS_1251868] 21, 2020   
 Confidential  21  
• Coronary angiogram and angioplasty. 
• Echocardiography and cardiac magnetic resonance. 
• Laboratory tests including CK- MB 
• Monitoring in the Intensive Care Unit. 
• Medications.  
 
7.2 LABORATORY PROCEDURES/EVALUATIONS  
 
A Schedule of Procedures is included in Section 7.3.6. 
 7.2.1 CLINICAL LABORATORY EVALUATIONS  
 The following laboratory evaluations will be performed. 
 
• Hematology: hemoglobin, hematocrit, white blood cells (WBC) with differential count, platelet count.  
• Biochemistry: sodium, potassium, carbon dioxide, chloride, blood urea nitrogen, creatinine, total bilirubin, total protein, albumin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline 
phosphatase. 
• High -sensitivity CRP  
• Pharmacokinet ics: SP16 conce ntration  
• Pregnancy test  (if indicated) 
 7.2.[ADDRESS_1251869]’s unique study identifier.  
 7.2.4 SPECIMEN SHIPMENT  
 The drug will be shipped on dry ice using GMP procedures (Global Courier) from the manufacturing site in the [LOCATION_006] to the pharmacy at VCU.  The entire drug supply for phase I would arrive in one shipment. The boxes and vials are labelled  (see label  sample ). 
 
Safety, Tolerability, and Efficacy of SP16  in STEMI  
Protocol Number [ADDRESS_1251870] 21, 2020   
 Confidential  22  
7.3 STUDY SCHEDULE  
 
7.3.1 SCREENING  
 
• Review medications history to determine eligibility based on inclusion/exclusion criteria.  
• Perform medical examinations needed to determine eligibility based on inclusion/exclusion criteria.  
• Physical examination, including vital signs 
• ECG  
• Review of all stu dy procedures and answer any participant questions 
• Obtain informed consent 
• Collect demographic information  
• Collect blood for baseline pharmacokinetics, comprehensive metabolic panel, CRP, complete blood cell count, and pregnancy test  (if appropriate). 
 7.3.2 DOSING ( after PCI ) 
 
• Re-verify that subject meets inclusion/exclusion criteria  upon completion of reperfusion. 
• Review coronary angiogram  
• Administer dose of SP16 (0.200 mg/kg, up to 12 mg) within 6 hours of reperfusion  
• Blood samples for pharmacokinetics will be collected at 30 +/ - 15 min, 90 +/ - 15 min, 180 
+/- 15 min and after SP16 administration  
 7.3.3 DISCHARGE  (or [ADDRESS_1251871] ) 
 
• Blood samples for hsCRP , safety labs (CBC, CBMP) and pharmacokinetics will be 
collected at 72 hours (or at discharge, whichever comes first). 
• Assess patient for adverse events  
• Record adverse events as reported by [CONTACT_3445]  
 
7.3.4 VISIT 4: FOLLOW -UP VISIT (Day 14 +/- 2) 
 
• History and physical exam 
• Blood sample for safety laboratory tests (CBC, CMP)  
• Blood sample for hs CRP   
• Assess patient for adverse events  
• Record adverse events as reported by [CONTACT_3445].  
 

Safety, Tolerability, and Efficacy of SP16  in STEMI  
Protocol Number [ADDRESS_1251872] 21, 2020   
 Confidential  23 7.3.4 VISIT 5: FOLLOW -UP VISIT 2 (Day 90 +/-14) 
 
• History and physical exam 
• Blood sample for safety laboratory tests (CBC, CMP) 
• Assess patient for adverse events  
• Record adverse events as reported by [CONTACT_3445].  
 
7.3.5 VISIT 6: FOLLOW -UP VISIT 3 (Day 365 +/- 30) 
 
• History and physical exam 
• Assess patient for adverse events  
• Transthoracic echocardiography 
• Record adverse events as reported by [CONTACT_3445].  
 
7.3.[ADDRESS_1251873] 21, 2020, every patient admitted to the hospi[INVESTIGATOR_893722] a nasopharyngeal swab at time of admission. P atients being seen in the outpatient clinics will be 
screened by [CONTACT_119907].  7.3.7 SCHEDULE OF EVENTS TABLE 
 
 
 
 Procedures  Screening  Dosing  Initial Inpatient  
(6 hours)  Discharge  
(or 72 hours)  Follow -up 
(14 days)  Follow -up 2  
(90 days)  Follow -up 3  
(365 days)  
Informed consent  X X      
Verify subject meets inclusion/exclusion 
criteria  X X      
Demographics  X       
Screening (and testing) for SARS -CoV2 virus*  X    X X X 
Medical history and physical examination  X   X X X X 
CBC w/diff, pltsa X   X X X  
Comprehensive metabolic panela X   X X X  
Serum Pregnancy testb X       
ECGa X       
Administer SP16 or matching placebo   X      
hsCRP  X   X X   
Pharmacokinetic analysis  X  Xc     
Echocardiography    Xa    X 
Subject interview for adverse events     X X X X 
Record adverse events if and as reported by 
[CONTACT_3445]    X X X X X 
*per VCU Health standard of care  
aIf not already performed for routine care  
bIf applicable  
cDrawn at 0, [ADDRESS_1251874] of the study such as rash or allergic/anaphylactic reactions . There will be no restrictions with respect to the type or nature of rescue medications, 
treatments and procedures, which will be chosen at the discretion of a licensed study physician.  7.9 PARTICIPANT ACCESS TO STUDY AGENT AT STUDY CLOSURE  
 The investigational drug will not be available outside the study. 
 
8 ASSESSMENT S OF SAFETY  
 
8.1 SPECIFICATION OF SAFETY PARAMETERS  
 
All adverse events ( AEs) that occur during the study will be recorded. At each study visit, subjects 
will be interviewed to identify any AEs  that have occurred. In addition, physical examinations, 
laborato ry tests and other pre- specified assessments will be evaluated to identify AEs . 
 Risks to subjects will be minimized by [CONTACT_893737]. 
 
8.1.1 DEFINITION OF ADVERSE EVENTS (AE)  
 Adverse event means any untoward medical occurrence associated with the use of an intervention 
in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). 
Safety, Tolerability, and Efficacy of SP16  in STEMI  
Protocol Number [ADDRESS_1251875] 21, 2020   
 Confidential  25 Note: Laboratory/ECG/vital signs abnormalities are not an AE  in themselves unless clinically 
relevant or m eet the definition of an AE . 
 
8.1.2 DEFINITION OF SERIOUS ADVERSE EVENTS (SAE)  
 Serious adverse event or serious suspected adverse reaction . An AE or suspected adverse reaction 
is considered "serious" if, in the view of either the investigator or sponsor, it results in any of the 
following outcomes: death, a life -threatening adverse event, inpatient hospi[INVESTIGATOR_8448], a persistent or significant incapacity or substantial 
disruption of the ability to conduct normal life functions, or a congenital anomaly/birth defect. Important medical events that may not result in death, be life -threatening, or require 
hospi[INVESTIGATOR_708], based upon appropriate medical judgment, they may jeopardize the pat ient or subject and may require medical or surgical intervention to prevent 
one of the outcomes listed in this definition. Examples of such medical events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient hospi[INVESTIGATOR_059], or the development of drug dependency or drug abuse.  8.1.3 DEFINITION OF UNANTICIPATED PROBLEMS (UP)  
 The office of human research protection ( OHR
 P) considers unanticipated problems involving 
risks to participants or others to include, in general, any incident, experience, or outcome that meets all of the following criteria:  
 
• Unexpected in terms of nature, severity, or frequency given (a) the research procedures that are described in the protocol -related documents, such as the IRB-approved research 
protocol and informed consent document; and (b) the characteristics of the participant population being studied; 
• Related or possibly related to participation in the research (“possibly related” means 
there is a reasonable possibility that the incident, experience, or outcome may have been caused by [CONTACT_3459]); and 
• Suggests that the research places participants or others at a greater risk of harm (including physical, psychological, economic, or social harm) than was previously known or recognized.  
 
This study will use the OHRP definition of UP. 
 
8.2 CLASSIFICATION OF AN ADVERSE EVENT  
 8.2.1 SEVERITY OF EVENT  
 For AEs not included in the protocol defined grading system, the following guidelines will be used to describe severity.  
• Mild – Events require minimal or no treatment and do not interfere with the participant’s daily activities.  
• Moderate – Events result in a low level of inconvenience or concern with the therapeutic measures. Moderate events may cause some interference with  
Safety, Tolerability, and Efficacy of SP16  in STEMI  
Protocol Number [ADDRESS_1251876] 21, 2020   
 Confidential  26 functioning. 
• Severe – Events interrupt a participant’s usual daily activity and may require 
systemic drug therapy or other treatment. Severe events are usually potentially life -
threatening or incapacitating.  
 
8.2.2 RELATIONSHIP TO STUDY AGENT  
 For all collected AEs, the clinician who examines and evaluates the participant will determine the AE’s causality based on temporal relationship and his/her clinical judgment. The degree of certainty about causality will be graded using the categories below.  
• Definitely Related – There is clear evidence to suggest a causal relationship, and other possible contributing factors can be ruled out. The clinical event, including an abnormal laboratory test result, occurs in a plausible time relationship to drug administration and cannot be explained by [CONTACT_9153]. The response to withdrawal of the drug (de-challenge) should be clinically plausible. The event must be pharmacologically or phenomenologically definitive, with use of a satisfactory re-challenge procedure if  necessary.  
• Probably Related – There is evidence to suggest a causal relationship, and the influence of other factors is unlikely. The clinical event, including an abnormal laboratory test result, occurs within a reasonable time after administration of the drug, is unlikely to be attributed to  concurrent  disease or other drugs or chemicals, and follows a clinically 
reasonable response on withdrawal (de- challenge). Re-challenge information is not 
required to fulfill this definition.  
• Possibly Related – There is some evidence to suggest a causal relationship (e.g., the event occurred within a reasonable time after administration of the trial medication). However, other factors may have contributed to the event (e.g., the participant’s clinical condition, other concomitant events). Although an AE may rate only as “possibly related” soon after discovery,  it can be flagged as requiring more information and later 
be upgraded to “probably related” or “definitely related,” as  appropriate. 
• Unlikely to be related – A clinical event, including an abnormal laboratory test result, whose temporal relationship to drug administration makes a causal relationship improbable (e.g., the event did not occur within a reasonable time after administration of the trial medication) and in which other drugs or chemicals or underlying disease provides plausible explanations (e.g., the pa rticipant’s clinical condition, other 
concomitant treatments).  
• Not Related – The AE is completely independent of study drug administration, and/or evidence exists that the event is definitely related to another etiology. There must be an alternative, defin itive etiology documented by [CONTACT_15370].  
 
8.2.[ADDRESS_1251877] 21, 2020   
 Confidential  27 The occurrence of an AE or serious adverse event ( SAE ) may come to the attention of study 
personnel during study visits and interviews of a study participant presenting for medical care, or 
upon review by a study monitor.  All AEs including local and systemic reactions not meeting the criteria for SAEs will be captured on the appropriate case report form . Information to be collected includes event description, time of 
onset, clinician’s assessment of severity, relationship to study product (assessed only by [CONTACT_214527] a diagnosis), and time of resolution/stabilization of the event.  
 All AEs occurring while on study must be documented appropriately regardless of relationship. All AEs will be followed to adequate resolution.  Changes in the severity of an AE will be documented to allow an assessment of the duration of the event at each level of severity to be performed. AEs characterized as intermittent require documentation of onset and duration of each epi[INVESTIGATOR_1865].  The PI [INVESTIGATOR_15356] 7 days after the administration of investigational medication . At each study visit, 
the investigator will inquire about the occurrence of AE/SAEs since the last visit. Events will be followed for outcome information until resolution or stabilization.  
 8.4 REPORTING PROCEDURES  
 8.4.1 ADVERSE EVENT REPORTING  
 Adverse (non- serious) events will be reported to the IRB on an annual basis and to the Sponsor at 
designated Safety Review milestones.  
 8.4.2 SERIOUS ADVERSE EVENT REPORTING  
 The investigators will report all adverse events to the Sponsor and local IRB. Serious, unexpected 
adverse events will be reported to the local IRB and to the Sponsor within 5 business days . All 
other AEs (unexpected but not serious or expected) will be reported to the Sponsor as a summary during follow up and at the completion of the study. All other AEs will be reported to the IRB at the time of regular (i.e. yearly) continuing review submissions.  The Sponsor will report all serious, unexpected adverse events as an IND safety report to the F
DA no later than 15 calendar days after the sponsor’s initial receipt of this information. Fatal or 
life-threatening unexpected experiences for which there is a possibility that the experience may 
have been caused by [CONTACT_893738] [ADDRESS_1251878] 21, 2020   
 Confidential  28 The study Sponsor will be responsible for notifying FDA of any unexpected fatal or life-
threaten ing suspected adverse reaction as soon as possible but in no case later than 7 calendar 
days after the Sponsor's init ial receipt of the information.  
 8.4.3 UNANTICIPATED PROBLEM REPORTING  
 Incidents or events that meet the OHRP criteria for UPs require the creation and completion of an 
UP report form. It is the S ite Investigator’s responsibility to report UPs to their IRB and to the 
Study Sponsor.  
 To satisfy the requirement for prompt reporting, UPs will be reported using the following timeline:  
• UPs will be reported to the IRB and to the study Sponsor within [ADDRESS_1251879] will be excluded from participation. Pregnancy that occurs after receipt of investigational medicine will p rompt reporting to the patient’s primary physician for appropriate monitoring and 
follow-up. 
 8.[ADDRESS_1251880] ( DSMB ) members within 24 
hours of becoming awa re and will provide the DSMB with AE listing reports. The DSMB will 
convene an ad hoc meeting by [CONTACT_145862]. The DSMB wi ll 
provide recommendations for proceeding with the study to the Study Sponsor and Principal Investigators. The Study Sponsor will inform the FDA of the temporary halt and the disposition of the study.  Enrollment in the study will be terminated if the any of following occur: 
• Serious adverse event , if determined to be probably or definitely related to the 
investigational medication in a patient who have received  SP16  or is unexpected in nature.  
 
Enrollment in the study will be halted until joint review by [CONTACT_893739]: 
• Two identical unexpected serious adverse events  in two separate subjects . 
 
In addition, the Principal Investigators may choose to halt enrollment, if in their opi[INVESTIGATOR_1649], continued enrollment would pose an unacceptable risk to subjects. Additional description of halting and stoppi[INVESTIGATOR_893723]  5.5. 
Safety, Tolerability, and Efficacy of SP16  in STEMI  
Protocol Number [ADDRESS_1251881]. The committee will meet at the end of the study and adjudicate all the events. The committee will be blinded to treatment allocation. In order to favor allocation concealment, the committee will also be blinded to C -
reactive protein levels, which may be affected by [CONTACT_3148].  
 8.7.2 Definition of the events  The events adjudicated will include:  
- Death;  
- Cardiac death (in which a direct cause attributable to cardiac disease is present);  
- Sudden cardiac death (in which cardiac death occurred out of the hospi[INVESTIGATOR_199542]; or in the hospi[INVESTIGATOR_893724]); 
- Non-cardiac death (in which the event of death is considered not to be a direct 
consequence of cardiac disease);  
- Incidence of heart failure during the index hospi[INVESTIGATOR_059] (defined as dyspnea beginning or persisting >24 hours after admission and meeting both of the following criteria:  
o physical signs of heart failure - including 2 or more of the following: edema, crackles/rales, jugular vein distention, hepatojugular reflex, tachypnea, rapid weight gain, S3 gallop, abdominal distension/ascites, radiologic evidence of worsening edema, pulmonary artery occlusive pressure (wedge) >18 mmHg or 
cardiac output <2.2 l/min-m2; 
o need for additional/increased heart failure therapy - including one of the 
following:   initiation or significant in crease of oral diuretics, requirement of 
intravenous diuretics, inotropes or vasodilators, need for ultrafiltration due to decompensated heart failure;  
- Re-hospi[INVESTIGATOR_10088]; 
- Re-hospi[INVESTIGATOR_19934] (meeting all criteria listed abov e for heart failure 
during index hospi[INVESTIGATOR_059]) 
- Incidence of heart failure (not hospi[INVESTIGATOR_057]) defined as new or worsening dyspnea and meeting one of the two of the following criteria: 
o physical signs of heart failure - including 2 or more of the following: edema, crackles/rales, jugular vein distention, hepatojugular reflex, tachypnea, rapid weight gain, S3 gallop, abdominal distension/ascites, radiologic evidence of 
Safety, Tolerability, and Efficacy of SP16  in STEMI  
Protocol Number [ADDRESS_1251882] 21, 2020   
 Confidential  30 worsening edema, pulmonary artery occlusive pressure (wedge) >18 mmHg or 
cardiac output <2.2 l/min -m2; 
o need for additional/increased heart failure therapy - including one of the following:   initiation or significant increase of oral diuretics, requirement of intravenous diuretics, inotropes or vasodilators, need for ultrafiltration due to decompensated heart failure;  
- Acute myocardial infarction, as defined by [CONTACT_199571] 
- Unstable angina, or need for coronary revascularization 
- Cardiac tachy - or brady-arrhythmias leading to a new hospi[INVESTIGATOR_893725]; 
- Acute renal failure (defined as in increase in plasma creatinine levels of 50% or 0.5 mg/L); 
- Acute respi[INVESTIGATOR_1399] (not due to heart failure); 
- Sepsis or other serious infection requiring antibiotic therapy; 
- Acute stroke.  
 
The analysis will consider time to first event and time to each event. It will also consider event rates at [ADDRESS_1251883] of the trial is in compliance with the currently approved protocol/amendment(s), with GCP, and with applicable regulatory requirement(s). Complete review of Case Report F orms will be performed  by [CONTACT_893740]! Reference source not found. . 
 10  STATISTICAL CONSIDERATIONS  
 
10.1 ANALYSIS DATASETS  
 
• All analyses will be conducted on the Safety Analysis Dataset (e.g., participants who received the investigational product). 
 
10.[ADDRESS_1251884] for continuous variables. An assessment of sample size or power analyses is 
not performed  for this pi[INVESTIGATOR_2268] P hase IB/ IIA study. A two -sided p-value < 0.05 will be considered 
statistically significant.  
 11 SOURCE DOCUMENTS AND ACCESS TO SOURCE DATA/DOCUMENTS  
 Virginia Commonwealth University will maintain appropriate medical and research records for this trial, in  compliance with ICH E6 and regulatory and institutional requirements for the protection of 
confidentiality of participa nts.  
 12 QUALITY ASSURANCE AND QUALITY CONTROL  
 The PIs  will oversee all data collection and recording on C ase Report F orms . They will periodically 
review C ase Report F orms . 
 13 ETHICS/PROTECTION OF HUMAN SUBJECTS  
 13.[ADDRESS_1251885]  
 Principal I nvestigators will ensure that this study is conducted in full conformity with Regulations 
for the Protection of Human Subjects of Research codified in 45 CFR Part 46, 21 CFR Part 50, 21 CFR Part 56, and/or the ICH E6.  13.[ADDRESS_1251886]  
 The protocol, informed consent form(s), recruitment materials, and all participant materials will be submitted to the  IRB for review and approval. Approval of both the protocol and the consent form 
must be obtained before any participant is enrolled. Any amendment to the protocol will require review and approval by [CONTACT_3484]. All changes to the consent form will be IRB approved; a determination will be made regarding whether previously consented participants need to be re-consented. Western Institutional Review Board (Puyallap, WA) will serve as the IRB of record for this study.  13.3 INFORMATED CONSENT PROCESS  
 13.3.1 CONSENT/ASSENT AND OTHER INFORMATIONAL DOCUMENTS 
PROVIDED TO PARTICIPANTS  
 All study pr ocedures will be completed after  to the subject consenting with the exception of 
screening under a waiver of consent. Those individuals unable to provide consent and in whom a legally authorized representative cannot be found to consent will be automatical ly excluded from 
the study. Only appropriately trained investigators will attempt to obtain informed consent to participate in the study. Considering, the emergency nature of the condition, we will request the 
Safety, Tolerability, and Efficacy of SP16  in STEMI  
Protocol Number [ADDRESS_1251887] to approve a short consent form to be followed by a full-length 
consent form.  
 
13.3.2 CONSENT PROCEDURES AND DOCUMENTATION  
 Informed consent is an ongoing process that is initiated prior to the individual’s agreeing to participate in the study and continues throughout the individual’s study participation. Extensive 
discussion of risks and possible benefits of participation will be provided to the participants and 
their families. Consent forms will be IRB -approved and the participant will be asked to read and 
review the docum ent. The investigator will explain the research study to the participant and 
answer any questions that may arise. All participants will receive a verbal explanation in terms suited to their comprehension of the purposes, procedures, and potential risks of the study and of their rights as research participants. When a potential candidate is identified, he or she will be provided with a consent form that explains the purposes of the study, the study procedures, the potential risks of participation, and all other requisite information as required by [CONTACT_2371]. The consent form will also explain that continuation in the study is “voluntary” and that the patient has “the right to withdraw from the study at any time”.  A copy of the informed consent document will be 
given to the participants for their records. 
 13.[ADDRESS_1251888] by [CONTACT_3486], their staff, and the sponsor(s) and their agents. This confidentiality is extended to cover testing of biological samples in addition to the clinical information relating to participants. Therefore, the study protocol, documentation, data, and all other information generated will be held in strict confidence. 
• Coded identifiers will be attached to data  or samples . 
• The key to coded identifiers will be stored in a password- protected database compliant 
with local standards and will be accessible only to the research team. Case Report F orms 
and written informed consent forms will be stored in a locked cabinet within a locked office with access restricted to the study team.  
• Coded data and samples, but not the key, will be shared with the Sponsor. 
 
The study participant’s contact [CONTACT_83955]. At the end of the study, all records will continue to be kept in a secure location for as long a period as dictated by [CONTACT_46202]. 
 
13.4.1 RESEARCH USE OF STORED HUMAN SAMPLES, SPECIMENS OR DATA  
 
• Intended Use: Samples and data collected under this protocol may be used to accomplish the objective of this study.  No genetic testing will be  performed.  
• Storage: Access to stored samples will be limited using  physical restrictions to locked 
storage areas and coded identifiers . Samples and data will be stored using codes 
assigned by [CONTACT_473]. Data will be kept in password- protected computers.  Only investigators will have access to the samples and data.  
 
13.[ADDRESS_1251889] KEEPI[INVESTIGATOR_1645]  
 
14.1 DATA COLLECTION AND MANAGEMENT RESPONSIBILITIES  
 
Data collection is the responsibility of the clinical trial staff at the site under the supervision of the 
site PI. The investigator is responsible for ensuring the accuracy, completeness, legibility, and 
timeliness of the data reported.  
 All source documents should be completed in a neat, legible manner to ensure accurate interpretation of data. Black ink is required to ensure clarity of reproduced copi[INVESTIGATOR_014]. When making changes or corrections, cross out the original entry with a single line, and initial and date the change.  Clinical data (including AEs, concomitant medications, and expected adverse reactions 
data) and cli nical laboratory data will be entered onto C ase Report F orms.  
 14.[ADDRESS_1251890], whichever is later. No records will be destroyed without the written consent of the Sponsor, if applicable. It is the responsibility of the Sponsor to inform the investigator when these documents no longer need to be retained.  14.3 PROTOCOL DEVIATIONS  
 A protocol deviation is any noncompliance with the clinical trial protocol, GCP, or MOP  
requirements. The noncompliance may be either on the part of the participant, the investigator, or the study site staff. As a result of deviations, corrective actions are to be developed by [CONTACT_3483].  
 These practices are consistent with ICH S7A, B:
16,17 
• 4.5 Compliance with Protocol, sections 4.5.1, 4.5.2, and 4.5.3 
• 5.1 Quality Assurance and Quality Control, section 5.1.1 
• 5.[ADDRESS_1251891] be addressed 
in study source documents, reported to the local IRB per their guidelines. The site PI/study staff is responsible for knowing and adhering to their IRB requirements.   14.[ADDRESS_1251892] that is appropriate to their participation in the trial.   
  
17 APPENDIX  
 
Version  Date  Significant Revisions  
v.1 12/13/2019  Initial version  
v.2 03/27/[ADDRESS_1251893] 21, 2020   
 Confidential  35 18 LI TERATURE REFERENCES   
 
1 Benjamin EJ, Muntner P, Alonso A, et al. Heart Disease and Stroke Statistics -2019 Update: A 
Report From the American Heart Association. Circulation. 2019 Mar 5;139(10):e56-e528. 
2 Velagaleti R, Pencina M, Murabito J, et al. Long -term trends in the incidence of heart failure a fter 
myocardial infarction. Circulation 2008;118:2057-2062.  
3 Frangogiannis NG, Smith CW , Entman ML. The inflammatory response in myocardial infarction. 
Cardiovasc Res 2002;53:3147.  
[ADDRESS_1251894] 
prognosis after revascularized STEMI. Eur J Intern Med 2010;21:131136  
5 Lewis EC. Expanding the clinical indications for a(1)-antitrypsin therapy. Mol Med 
2012;18:957e970. 
6 AAT in murine MI Toldo S, Seropi[INVESTIGATOR_86778], Mezzaroma E, et al. Alpha-1 antitrypsin inhibits caspase-
1 and protects from acute myocardial ischemia- reperfusion  injury. J Mol Cell Cardiol 2011;51:244-
51.  
7 Gooptu B, Lomas DA. Conformational pathology of the serpi[INVESTIGATOR_2115]: themes, variations, and therapeutic 
strategies. Annu Rev Biochem. 2009 Jan;78:147–76. 
8 Strickland DK, Muratoglu SC, Antalis TM. Serpin- Enzyme Receptors LDL Receptor -Related 
Protein 1. Methods Enzymol. 2011;499:17–31.  
9 Perlmutter DH, Joslin G, Nelson P, Schasteen C, Adams SP, Fallon RJ. Endocytosis and 
degradation of alpha 1- antitrypsin -protease complexes is mediated by [CONTACT_893741] -enzyme complex 
(SEC) receptor. J Biol Chem. [ADDRESS_1251895] 5;265(28):[ZIP_CODE]–6. 
10 Toldo S, Austin D, Mauro AG, Mezzaroma E , Van Tassell  BW, Marchetti C, Carbone S, 
Mogelsvang  S, Gelber  S, Abbate A. Low-Density Lipoprotein Receptor–Related Protein -[ADDRESS_1251896] 30;2(5):561-
574.  
11 Abbate A, Van Tassell BW, Christopher S, et al. Effects of Prolastin C (Plasma -Derived Alpha -1 
Antitrypsin) on the acute inflammatory response in patients with ST- segment elevation myocardial 
infarction (from the VCU- alpha 1 -RT pi[INVESTIGATOR_799]). Am J Cardiol 2015;115(1):8–12. 
[ADDRESS_1251897] -segment elevation acute myocardial 
infarction (from the VCU- ART and VCU-ART2 pi[INVESTIGATOR_7602]). Am J Cardiol. 2015. 
13 Van Tassell BW, Lipi [INVESTIGATOR_256794], Appleton D, Roberts CS, Kontos MC, Abouzaki N, et al. Rationale 
and design of the Virginia Commonwealth University–Anakinra Remodeling Trial- 3 (VCU -ART3): 
A randomized, placebo-controlled, double- blinded, multice nter study. Clin Cardiol. 2018. 
Safety, Tolerability, and Efficacy of SP16  in STEMI  
Protocol Number [ADDRESS_1251898] 21, 2020   
 Confidential  36 14 Abouzaki NA, Christopher S, Trankle C, Van Tassell BW, Carbone S, Mauro AG, Buckley L, 
Toldo S, Abbate A. Inhibiting the Inflammatory Injury After Myocardial Ischemia Reperfusion With 
Plasma -Derived Alpha -1 Antitrypsin: A Post Hoc Analysis of the VCU- α1RT Study. J Cardiovasc 
Pharmacol . 2018. 
15 Nagueh SF, Appleton CP, Gillebert TC, et al. Recommendations for the evaluation of left 
ventricular diastolic function by [CONTACT_51541]. J Am Soc Echocardiogr 2009;22:107133.  
16 ICHS7A -  
http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S7A/Step4/S7A_G
uideline.pdf  
7 ICHS7b - 
http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S7B/Step4/S7B_G
uideline.pdf 
 